TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) has been given an average rating of “Moderate Buy” by the six brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $29.00.
Several brokerages have issued reports on TGTX. JPMorgan Chase & Co. restated an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a research report on Thursday. The Goldman Sachs Group boosted their target price on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. StockNews.com lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of TG Therapeutics in a report on Thursday. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $39.00 price target on shares of TG Therapeutics in a report on Thursday.
Read Our Latest Analysis on TGTX
Insider Activity at TG Therapeutics
Institutional Trading of TG Therapeutics
Hedge funds have recently bought and sold shares of the stock. Pingora Partners LLC purchased a new stake in TG Therapeutics during the fourth quarter worth $27,000. Coppell Advisory Solutions LLC purchased a new stake in TG Therapeutics during the second quarter worth $46,000. Providence Capital Advisors LLC lifted its holdings in TG Therapeutics by 1,403.9% during the first quarter. Providence Capital Advisors LLC now owns 1,910 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,783 shares during the period. KBC Group NV purchased a new stake in TG Therapeutics during the fourth quarter worth $54,000. Finally, PNC Financial Services Group Inc. increased its position in shares of TG Therapeutics by 131.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,014 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.
TG Therapeutics Trading Up 1.2 %
Shares of NASDAQ TGTX opened at $13.99 on Friday. The business’s 50 day moving average is $15.13 and its two-hundred day moving average is $13.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $35.67. The stock has a market capitalization of $2.16 billion, a P/E ratio of 699.85 and a beta of 2.30.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The business had revenue of $43.97 million during the quarter, compared to analyst estimates of $40.06 million. During the same quarter in the previous year, the business earned ($0.39) earnings per share. As a group, research analysts expect that TG Therapeutics will post -0.12 EPS for the current year.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Further Reading
- Five stocks we like better than TG Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Comprehensive PepsiCo Stock Analysis
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.